Table 1.

Baseline Patient Pathologic and Clinical Characteristics

Baseline Characteristics	N = 22
Age (years)
Median	70.5
(Range)	(51–84)
Gleason sum at diagnosis, N (%)
≤7	9 (40.9%)
8	2 (9.1%)
9	8 (36.4%)
10	3 (13.6%)
Baseline PSA (ng/mL)
Median	41.1
(Range)	(2.4–366)
Lines of prior novel AR targeted therapy, N (%)
0	4 (18.2%)
1	9 (40.9%)
2	9 (40.9%)
Prior taxane chemotherapy, N (%)
Yes	2 (9.1%)
No	20 (90.9%)
NGS mutation profile, N (%)
TP53 and/or HRD	15 (68.2%)
Unknown	7 (31.8%)

AR = androgen receptor; HRD = homologous recombination DNA repair gene; N = number of patients; NGS = next-generation sequencing; PSA = prostate-specific antigen.